FAERS‐Based Pharmacovigilance Study on Drug‐Induced Extrapyramidal Disorder: Risk Signals and Mechanistic Insights
Advances in Pharmacological and Pharmaceutical Sciences · 2026-01 · 2026 (1)
DOI: 10.1155/adpp/2411874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Pharmacological and Pharmaceutical Sciences, online erschienen am 17.04.2026. Verfasst von Hao Wen und 2 weiteren Autor:innen. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Province Medical Science Research Key Project, Chengde Medical University.
Abstract (Originalsprache)
Purpose
This study aimed to identify high‐risk drugs for drug‐induced extrapyramidal disorder (EPD) and explore their molecular mechanisms by integrating pharmacovigilance analytics with genetic and computational approaches.
Methods
We performed disproportionality analysis on FAERS data (2004–2024) to detect EPD signals, time‐to‐onset analysis to assess risk timing, Mendelian randomization (MR) to infer causal effects of drug–target gene expression (e.g., HTR1D, ADRA2B) on EPD risk, and molecular docking to evaluate drug–target binding affinities.
Results
Metoclopramide, risperidone, and haloperidol decanoate showed the strongest EPD signals. TTO analysis revealed an early failure pattern (Weibull β < 1), indicating highest risk during initial treatment. MR identified brain‐expressed HTR1D and ADRA2B as causally linked to EPD risk. Molecular docking confirmed strong binding of risperidone and paliperidone to these targets.
Conclusions
This study is the first to integratively link pharmacovigilance signals with genetic causality and structural binding insights for EPD. Our findings support deprescribing high‐risk agents, preemptive genetic screening, and enhanced early monitoring to mitigate drug‐induced EPD, offering a translational framework for precision pharmacovigilance.
Förderung
- Hebei Province Medical Science Research Key Project
- Chengde Medical University
Zitieren
APA
Wen, H., Xu, W., & Wang, R. (2026). FAERS‐Based Pharmacovigilance Study on Drug‐Induced Extrapyramidal Disorder: Risk Signals and Mechanistic Insights. Advances in Pharmacological and Pharmaceutical Sciences, 2026(1). https://doi.org/10.1155/adpp/2411874
Vancouver
Wen H, Xu W, Wang R. FAERS‐Based Pharmacovigilance Study on Drug‐Induced Extrapyramidal Disorder: Risk Signals and Mechanistic Insights. Advances in Pharmacological and Pharmaceutical Sciences. 2026;2026(1). doi:10.1155/adpp/2411874
BibTeX
@article{Wen2026,
author = {Wen, Hao and Xu, Wenfang and Wang, Ruiting},
title = {FAERS‐Based Pharmacovigilance Study on Drug‐Induced Extrapyramidal Disorder: Risk Signals and Mechanistic Insights},
journal = {Advances in Pharmacological and Pharmaceutical Sciences},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/adpp/2411874}
}
EUVIMED